Health workers collect swab samples on Narkeldanga Main Road Kolkata
Former Union Minister Raghuvansh Prasad Singh passed away on Sunday morning while undergoing treatment in New Delhi. Singh, who had recently resigned from RJD, had fallen seriously ill after developing post-COVID complications. Singh’s condition had deteriorated by Friday evening and he was admitted to AIIMS on Saturday with complaints of a recurrent cough. The 74-year-old man was later hooked up to a ventilator.
Union Interior Minister Amit Shah was admitted to the AIIMS in Delhi on Saturday for a “full medical checkup” before Monday’s monsoon session of parliament. He will remain in the hospital for 1-2 days, a statement issued by the medical institute said on Sunday. This comes nearly two weeks after the 55-year-old BJP leader was discharged from the higher medical institute for Covid aftercare. This is your second visit to the hospital in more than a month.
A study on the first national serosurveillance to estimate the prevalence of the new coronavirus, carried out in May, shows that up to 8.56 lakh of cases were present in the 233 districts considered ‘without load of cases’ at that time, confirming the underdetection. of cases in the country. While an independent group of experts began investigating the serious illness in one participant that led to the suspension of clinical trials of AstraZeneca’s coronavirus vaccine, the World Health Organization said there was nothing to be discouraged about. that these types of incidents occur routinely during rehearsals.
Meanwhile, trials of the vaccine in India, which is being carried out by the Pune-based Serum Institute of India, have also stopped. On Wednesday, Serum claimed that India’s trials would not be affected by AstraZeneca’s decision. However, the officer of the Comptroller General of Drugs of India issued a notice of show of cause, and on Thursday, Serum said it would suspend the trials in India. So far, the vaccine has been administered to 100 participants in India, where combined phase 2 and phase 3 trials were approved last month. About 1,600 participants were planned to enroll for the full trial.
In Geneva, WHO chief scientist Soumya Swaminathan said the AstraZeneca hiatus was not a setback and nothing to be discouraged from. He said the incident just showed that the vaccine development process was not always a “fast and straightforward path.”
.
